• Mitochondrial Nde1: Integrative Sentinel for Yeast Cell Fate

  2026-06-03

  Saladi et al. (2020) reveal that the yeast mitochondrial NADH dehydrogenase Nde1 acts as both a metabolic enzyme and a sensor that triggers apoptosis in response to respiratory dysfunction. Their findings provide a mechanistic basis for how mitochondria can selectively eliminate compromised cells, with implications for understanding proteostasis and cell quality control.

• Advancing Translational Oncology: ECL Chemiluminescence for

  2026-06-03

  This thought-leadership article examines the mechanistic foundations and translational impact of ECL chemiluminescence in protein analysis, with special focus on the APExBIO ECL Chemiluminescent Substrate Detection Kit. By analyzing its role in validating emerging therapeutic strategies for renal cell carcinoma, such as the combination of syringin and sunitinib, we explore best practices, workflow optimizations, and future perspectives for translational researchers.

• IR-1061: Benchmark Near Infrared Fluorescent Dye for Deep Im

  2026-06-02

  IR-1061 is a near infrared fluorescent dye optimized for high-contrast, deep-tissue imaging due to its strong OTN-NIR emission and minimal background autofluorescence. Its solubility profile and robust quality controls make it a reference compound for advanced biomedical research and molecular imaging workflows.

• Dual-Action Kinase Inhibitors Promote p38α Dephosphorylation

  2026-06-02

  This study uncovers how certain kinase inhibitors, including Imatinib hydrochloride, not only inhibit kinase activity but also enhance the dephosphorylation of p38α MAP kinase by stabilizing a phosphatase-accessible conformation. These dual-action effects reveal new avenues for designing more efficient and selective kinase inhibitors in cancer and signaling research.

• CLCC1 Identified as Key Host Factor in Herpesvirus Nuclear E

  2026-06-01

  A recent study has uncovered CLCC1 as a crucial cellular mediator of membrane fusion during herpesvirus nuclear egress, using whole-genome CRISPR screening. This finding clarifies a longstanding gap in our understanding of herpesvirus replication and presents new possibilities for antiviral strategy development.

• BMN 673 (Talazoparib): Precision PARP Inhibition in DNA Repa

  2026-06-01

  BMN 673 (Talazoparib) stands out for its exceptional potency and selectivity as a PARP1/2 inhibitor, enabling robust detection of homologous recombination deficiencies and DNA repair vulnerabilities in cancer models. This article delivers actionable experimental workflows, troubleshooting insights, and context from cutting-edge BRCA2–RAD51 research to help maximize the translational value of BMN 673 in laboratory and preclinical settings.

• Practical Guidance for Omeprazole (A2845) in H+,K+-ATPase As

  2026-05-31

  Omeprazole (SKU A2845) is a potent H+,K+-ATPase inhibitor used in research to control and model gastric acid secretion and antiulcer mechanisms. This product is not suitable for diagnostic or therapeutic use, and its application is strictly limited to controlled laboratory workflows.

• DOT1L Inhibition Boosts Lenalidomide Response in Myeloma Mod

  2026-05-30

  This study reveals that DOT1L inhibition reprograms innate immunity and significantly enhances the anti-myeloma efficacy of lenalidomide (CC-5013). By mechanistically linking epigenetic regulation to interferon signaling and immunomodulatory drug response, the findings offer a new rationale for combination therapy in multiple myeloma.

• Mutational Landscape Analysis of Myeloma Cell Lines: Insight

  2026-05-29

  This article examines a comprehensive exome sequencing study of 30 human multiple myeloma cell lines, revealing recurrent driver mutations and key pathways involved in tumor progression and drug resistance. The findings offer actionable guidance for selecting cell line models and inform the design of experiments targeting hematological malignancies, including those involving immunomodulatory agents.

• Isoprinosine in Immunotherapy: Protocols and Workflow Advanc

  2026-05-29

  Isoprinosine (inosine pranobex) stands out for its dual immunomodulatory and antiviral activities, enabling robust inhibition of viral replication and precise modulation of immune responses in translational research. This article delivers actionable protocol enhancements, advanced use-cases, and troubleshooting strategies—linking recent mechanistic breakthroughs to practical laboratory decisions.

• RapaLink-1: mTOR Inhibition Redefined for Dormancy Modeling

  2026-05-28

  Explore how RapaLink-1, a third-generation mTOR inhibitor, is transforming in vitro embryonic dormancy modeling and cancer research. This article offers a novel, protocol-oriented perspective distinct from existing guides.

• Cy3 Goat Anti-Mouse IgG (H+L) Antibody: Protocols & QC Guide

  2026-05-28

  The Cy3 Goat Anti-Mouse IgG (H+L) Antibody provides sensitive, fluorescence-based detection for mouse IgG primary antibodies in immunofluorescence, flow cytometry, and western blot assays. It is suitable for workflows requiring robust signal amplification and clear visualization of mouse-derived targets. Not intended for diagnostic or medical applications; performance outside validated immunoassays is unproven.

• Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibi

  2026-05-27

  Anlotinib hydrochloride redefines angiogenesis and tumor biology research with nanomolar potency and superior selectivity across key tyrosine kinases. This guide delivers actionable protocols, experimental troubleshooting, and comparative insights to maximize research impact with this advanced anti-angiogenic small molecule.

• Cediranib (AZD2171) in Cancer Research: Protocols and Precis

  2026-05-27

  Cediranib (AZD2171) empowers cancer researchers with potent, selective inhibition of VEGFR-driven angiogenesis and downstream PI3K/Akt/mTOR signaling. This guide delivers actionable protocols, practical troubleshooting, and evidence-based insights for maximizing reproducibility and translational relevance in vitro.

• Translating PDGF Receptor Inhibition: JNJ-10198409 in Oncolo

  2026-05-26

  This thought-leadership article bridges mechanistic insight and translational strategy for researchers leveraging JNJ-10198409, a potent platelet-derived growth factor receptor inhibitor. We examine the rationale for targeting PDGF signaling, dissect experimental validation, and contextualize APExBIO’s compound in the evolving oncology and fibrosis research landscape. Drawing inspiration from host-pathogen signaling studies, the article highlights how precise kinase inhibition can transform disease modeling and intervention.

16605 records 1/1107 page Next 12345 下5页 Last page